FORM 4	
--------	--

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*]	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer						
		(Check all applicable)						
Liawatidewi Yakob	Amphastar Pharmaceuticals, Inc. [
	AMPH]	Director 10% Owner						
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X_Officer (give title below) Other (specify below)						
(Lust) (First) (Minute)		EVP Corp Admin Center						
C/O AMPHASTAR	8/8/2022							
PHARMACEUTICALS, INC., 11570								
6TH STREET								
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)						
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)		X _ Form filed by One Reporting Person Form filed by More than One Reporting Person						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Tub		i vanve see	ui itics i ic	quii	cu, Disp	Joseu o	, or D	chemenany Owned		
1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	(Instr. 8) or D		or Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D)	Beneficial
			Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	8/8/2022		М		5000	Α	\$19.79	66607	D	
Common Stock	8/8/2022		S ⁽¹⁾		5000	D	\$38.00	61607	D	
Common Stock	8/9/2022		М		3055	Α	\$19.79	64662	D	
Common Stock	8/9/2022		S ⁽¹⁾		3055	D	\$39.00	61607	D	
Common Stock								2459	I	See footnote <mark>(2</mark>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

						•	, (8,1		, I			,		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise f tive	3A. Deemed Execution Date, if any			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	Securities Beneficially Owned	Ownership Form of Derivative Security:	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Employee Stock Option (right to buy)	\$19.79	8/8/2022		М			5000	(3)	3/15/2028	Common Stock	5000	\$0	3055	D	
Employee Stock Option (right to buy)	\$19.79	8/9/2022		М			3055	<u>(3)</u>	3/15/2028	Common Stock	3055	\$0	0	D	

Explanation of Responses:

- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 5, 2022.
- (2) The reported shares are held of record by the Yakob and Sunmoon Trust dated July 25, 2013 for which the reporting person serves as a trustee.
- (3) Shares subject to the option are fully vested and immediately exercisable.

Reporting Owners

Bonorting Owner Name / Address		Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Liawatidewi Yakob C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730			EVP Corp Admin Center						

Signatures

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.